NZ513701A - Heteroaryl amidines, methylamidines and guanidines as protease inhibitors - Google Patents

Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Info

Publication number
NZ513701A
NZ513701A NZ513701A NZ51370199A NZ513701A NZ 513701 A NZ513701 A NZ 513701A NZ 513701 A NZ513701 A NZ 513701A NZ 51370199 A NZ51370199 A NZ 51370199A NZ 513701 A NZ513701 A NZ 513701A
Authority
NZ
New Zealand
Prior art keywords
methylamidines
guanidines
protease inhibitors
amidines
heteroaryl
Prior art date
Application number
NZ513701A
Inventor
M Jonathan Rudolph
Juan Jose Marugan
Carl R Illig
Naline L Subasinghe
James B Hoffman
Kenneth J Wilson
Original Assignee
Dimensional Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc
Publication of NZ513701A publication Critical patent/NZ513701A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ513701A 1999-02-09 1999-08-11 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors NZ513701A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24706299A 1999-02-09 1999-02-09

Publications (1)

Publication Number Publication Date
NZ513701A true NZ513701A (en) 2001-09-28

Family

ID=22933398

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ513701A NZ513701A (en) 1999-02-09 1999-08-11 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Country Status (19)

Country Link
EP (1) EP1150979A1 (en)
JP (1) JP2002536446A (en)
KR (1) KR20010098982A (en)
CN (1) CN1337961A (en)
AU (1) AU5671799A (en)
BG (1) BG105866A (en)
BR (1) BR9917036A (en)
CA (1) CA2362390A1 (en)
CZ (1) CZ20012858A3 (en)
EA (1) EA200100882A1 (en)
HU (1) HUP0201475A2 (en)
IL (1) IL144560A0 (en)
MX (1) MXPA01008084A (en)
NO (1) NO324887B1 (en)
NZ (1) NZ513701A (en)
PL (1) PL351767A1 (en)
SK (1) SK11422001A3 (en)
WO (1) WO2000047578A1 (en)
ZA (1) ZA200106849B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1152759A2 (en) * 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
AR039891A1 (en) * 2002-05-28 2005-03-09 Dimensional Pharm Inc THIOPHEN-AMIDINE COMPOUNDS, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES AND DISORDERS MEDIATED BY C1S
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1648862A2 (en) * 2003-07-10 2006-04-26 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication
JP2007524685A (en) 2004-02-12 2007-08-30 モレキュラー インサイト ファーマシューティカルズ インコーポレーティッド Technetium-bis (heteroaryl) and rhenium-bis (heteroaryl) complexes and methods of use thereof
JP5632379B2 (en) 2008-10-09 2014-11-26 アメリカ合衆国 Human pyruvate kinase activator
KR101722289B1 (en) 2009-07-08 2017-03-31 데르미라 (캐나다), 인코포레이티드 TOFA Analogs Useful in Treating Dermatological Disorders or Conditions
AU2011245441B2 (en) 2010-04-29 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CA2825306C (en) * 2011-01-25 2019-02-26 The Regents Of The University Of Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
AR086744A1 (en) * 2011-06-28 2014-01-22 Nippon Soda Co HETEROCICLIC COMPOUND CONTAINING NITROGEN AND FUNGICIDE FOR USE IN AGRICULTURE AND GARDENING
EP2606726A1 (en) * 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
EP2951170B1 (en) 2013-02-04 2018-10-24 Janssen Pharmaceutica NV Flap modulators
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
EP3778583A4 (en) * 2018-03-30 2022-01-05 Sumitomo Chemical Company Limited Heterocyclic compound and arthropod pest control composition containing same
CN109020837A (en) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 A kind of preparation method of 2- substituted-phenyl-B amidine hydrochloric acid salt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220654A (en) * 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4424367A (en) * 1982-08-19 1984-01-03 Norwich Eaton Pharmaceuticals, Inc. 5-(4-Aminophenyl)-2-thiophenecarboximidamide hydrochloride hemihydrate
JPS59139357A (en) * 1983-01-28 1984-08-10 Torii Yakuhin Kk Amidine derivative
DE3427865A1 (en) * 1984-07-27 1986-02-06 Torii & Co., Tokio/Tokyo Amidino compounds, process for their preparation and pharmaceutical compositions containing these compounds
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
EP0724435B1 (en) * 1993-10-21 2002-08-14 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
TW414795B (en) * 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
DE19632773A1 (en) * 1996-08-14 1998-02-19 Basf Ag New thrombin inhibitors
PE121699A1 (en) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
WO1999037611A1 (en) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors
KR100689923B1 (en) * 1998-01-26 2007-03-09 애보트 게엠베하 운트 콤파니 카게 Thrombin Inhibitors
CA2321025A1 (en) * 1998-02-09 1999-08-12 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
CA2319554C (en) * 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
KR20010042296A (en) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Benzoxazinones/Benzothiazinones as Serine Protease Inhibitors
AU763110B2 (en) * 1998-03-31 2003-07-10 Warner-Lambert Company Quinolones as serine protease inhibitors

Also Published As

Publication number Publication date
ZA200106849B (en) 2002-11-20
EA200100882A1 (en) 2002-04-25
WO2000047578A1 (en) 2000-08-17
MXPA01008084A (en) 2004-09-10
BG105866A (en) 2002-06-28
CN1337961A (en) 2002-02-27
BR9917036A (en) 2002-07-30
SK11422001A3 (en) 2002-04-04
KR20010098982A (en) 2001-11-08
NO324887B1 (en) 2007-12-27
JP2002536446A (en) 2002-10-29
CA2362390A1 (en) 2000-08-17
EP1150979A1 (en) 2001-11-07
IL144560A0 (en) 2002-05-23
NO20013853D0 (en) 2001-08-07
NO20013853L (en) 2001-10-09
AU5671799A (en) 2000-08-29
CZ20012858A3 (en) 2002-05-15
HUP0201475A2 (en) 2003-10-28
PL351767A1 (en) 2003-06-16

Similar Documents

Publication Publication Date Title
AU2001251063A1 (en) 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
HUP0300855A3 (en) Peptidmomimetic protease inhibitors, pharmaceutical compositions and their use
HUP0200347A2 (en) N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
ZA200210411B (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals.
ZA200210180B (en) Novel heteroaryl derivatives and the use thereof as pharmaceuticals.
PL351767A1 (en) Heteroaryl amidines, methylamidines and guanidines as protease inhibitors
IL159540A0 (en) Heterocyclic compounds as selective bacterial dhfr inhibitors and the uses thereof
MXPA03004848A (en) Guanidine and amidine derivatives as factor xa inhibitors.
AU2003271223A1 (en) Novel n-hydroxy thiourea, urea and amide compounds and the pharmaceutical compositions comprising the same
EP1235577A4 (en) Protease inhibitors
AU2424499A (en) Heterocyclic amidines as callicrein protease inhibitors
EP1232155A4 (en) Protease inhibitors
EP1229915A4 (en) Protease inhibitors
EP1229914A4 (en) Protease inhibitors
EP1229912A4 (en) Protease inhibitors
EP1231921A4 (en) Protease inhibitors
EP1351930A4 (en) Protease inhibitors
HK1043534A1 (en) Protease inhibitors
EP1233771A4 (en) Protease inhibitors
HK1044758A1 (en) Protease inhibitors
EP1229911A4 (en) Protease inhibitors
AU1039801A (en) Compounds and their use as cysteine protease inhibitors
EP1231923A4 (en) Protease inhibitors
EP1232154A4 (en) Protease inhibitors

Legal Events

Date Code Title Description
AVOD Application void